Source/Disclosures
Disclosures: The authors report no relevant financial disclosures.
September 15, 2020
1 min read
Save

Nonvalved aqueous drainage implant reduces IOP, glaucoma medications

Source/Disclosures
Disclosures: The authors report no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A low-cost nonvalved aqueous drainage implant significantly reduced IOP and glaucoma medication use in patients with refractory glaucoma, according to a retrospective review.

“The design inspiration of this cost-effective indigenously manufactured nonvalved device is the Baerveldt glaucoma implant (Johnson & Johnson Vision), which is not available in India. Its performance appears to be rather similar, and at 2 years, it has a low failure rate with achievement of low target intraocular pressure at substantially reduced number of medications,” study co-author Vanita Pathak Ray, FRCS (Ed), FRCOphth, told Healio/OSN.

The study included 48 eyes of 46 patients with refractory glaucoma who received an Aurolab aqueous drainage implant with at least 12 months of postoperative follow-up. Complete success was defined as IOP of 5 mm Hg or greater and 21 mm Hg or less, and qualified success was defined as reaching the IOP criteria with the use of glaucoma medications.

The median preoperative IOP was 33 mm Hg, and the median preoperative number of glaucoma medications was four.

At postoperative day 1, week 1, week 6, month 3, month 6, month 12, month 24 and final follow-up, median IOP was 25.5 mm Hg, 18 mm Hg, 8 mm Hg, 14 mm Hg, 12 mm Hg, 14 mm Hg, 14.5 mm Hg and 14 mm Hg, respectively. The IOP was significantly lower at each time point compared with the median baseline IOP (P < .001), and patients experienced an overall IOP reduction of 57.6%.

The number of glaucoma medications was zero at the last follow-up visit (P < .001).

Complete success was seen in 56.3% of eyes, and overall success was 87.5%. However, 21 complications occurred, and some eyes had more than one complication.

“This has tremendous implications in the management of refractory glaucoma in newly industrialized nations worldwide, as it has the ability to breach the cost barrier,” Ray said.